# The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

> **NCT00401245** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 500 (actual)

## Conditions studied

- Vasomotor Symptoms

## Interventions

- **DRUG:** desvenlafaxine succinate sustained release
- **DRUG:** desvenlafaxine succinate sustained release
- **DRUG:** desvenlafaxine succinate sustained release
- **DRUG:** desvenlafaxine succinate sustained release
- **DRUG:** Placebo
- **DRUG:** desvenlafaxine succinate sustained release
- **DRUG:** desvenlafaxine succinate sustained release
- **DRUG:** desvenlafaxine succinate sustained release

## Key facts

- **NCT ID:** NCT00401245
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2011-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00401245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00401245, "The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00401245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*